

### **DETAILED ACTION**

Claims 1, 3-7, 11-18, and 22 are pending in the instant application. Claims 2, 8-10 and 19-21 were cancelled by way of amendment filed on January 16, 2009. Claim 15 is cancelled by way of examiner's amendment. Claims 1, 3-7, 11-14, 16-18, and 22 are allowed.

#### ***Information Disclosure Statement***

The information disclosure statement filed on January 16, 2009 was considered and a signed copy of form 1449 is enclosed herewith.

#### ***Response to Amendment and Remarks***

The amendment and remarks filed on January 16, 2009 were fully considered and entered into the application. In regards to the 35 U.S.C. 112 1st paragraph rejection of claims 1-14 and 18, the rejection is moot in view of Applicants' amendment and the examiner's amendment which is described below. Therefore, the 35 U.S.C. 112 1st paragraph rejection has been withdrawn. In regards to the 35 U.S.C. 102(b), 102(a) and 102(e) rejections of claims 1-3, 5, 7, 9-12, 14, and 18, the rejections are moot in view Applicants' amendment. Therefore, the 35 U.S.C. 102(b), 102(a) and 102(e) rejections have been withdrawn. In regards to the provisional obviousness-type double patenting rejection of claims 1, 3, 4, 6, 10-14, and 18 over U.S. Application No. 11/577,476, Applicants' state that "if 'provisional' ODP rejections in two applications are the only rejections remaining in those applications, the examiner should withdraw the ODP rejection in the earlier filed application thereby permitting that application to issue without need of a terminal disclaimer." This has been found fully persuasive

Art Unit: 1626

and the provisional obviousness-type double patenting rejection has been withdrawn. Finally, in regards to the objection of claims 1-14 and 18, the objection has been withdrawn.

### **EXAMINER'S AMENDMENT**

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it **MUST** be submitted no later than the payment of the issue fee.

The claims have been amended as follows: claim 15 is cancelled.

In claim 16, line 1, "preventive and/or" is deleted from the claim.


In claim 1, lines 11-13, the following is deleted from the claim "and R<sup>2</sup> represents a group selected from among a hydrogen atom, a halogeno group, a hydroxyl group, a lower alkoxy group, and a lower alkyl group which may have a substituent;" (i.e., the definition of R<sup>2</sup> is deleted from the claim).

In claims 1, 3-7, 11-14, 16-18, and 22, before the phrase "a salt of the compound", the comma is replaced with "or" and "pharmaceutically acceptable" is inserted before "salt". Also, ", or a hydrate of the compound or the salt" is deleted from the claims. For example, the first two lines of claim 1 should read "A compound represented by formula (I) or a pharmaceutically acceptable salt of the compound:" and the last two lines in claim 22 should read "recited in claim 1 or a pharmaceutically acceptable salt of the compound."

### **REAONS FOR ALLOWANCE**

Art Unit: 1626

The compounds, therapeutic agents, platelet aggregation inhibitors, and pharmaceutical compositions of formula (I) and the method of using compounds of formula (I) are novel and non-obvious over the prior art because of the structural limitation that one of Ar1 and Ar2 is a 6-membered aromatic heterocyclic group. The closest prior art is Asker et al. (J. Org. Chem., 1961, 26 (5), 1440-1443) which discloses the following compounds



(page 1441) wherein R is phenyl (i.e., unsubstituted or

substituted with methyl) or naphthalene. The compounds disclosed in Asker et al. do not fit within the scope of the compounds of the instant claims (i.e., since there is not a 6-membered aromatic heterocyclic group bonded directly to the triazole ring) nor are they obvious variants. Therefore, the compounds disclosed in Asker et al. have different properties than the compounds of the instant claims.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

### **Conclusion**

Any inquiry concerning this communication or earlier communications from the examiner should be directed to KRISTIN BIANCHI whose telephone number

Art Unit: 1626

is (571)270-5232. The examiner can normally be reached on Mon-Fri 7am-3:30pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph McKane can be reached on 571-272-0699. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Kamal A Saeed/  
Primary Examiner, Art Unit 1626

Kristin Bianchi  
Examiner  
Art Unit 1626

\*\*\*